Radiopharm Theranostics Limited American Depositary Shares (RADX) is a publicly traded Healthcare sector company. As of May 21, 2026, RADX trades at $4.58 with a market cap of $37.45M and a P/E ratio of 0.00. RADX moved -0.22% today. Year to date, RADX is -10.20%; over the trailing twelve months it is +4.09%. Its 52-week range spans $3.50 to $50.82. Analyst consensus is buy with an average price target of $22.50. Rallies surfaces RADX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Radiopharm Theranostics Completes RAD 101 Phase 2b, Advances RAD 202 and First-in-Human Trials: Radiopharm Theranostics completed enrollment in its 30-patient Phase 2b RAD 101 imaging trial, reporting 90% MRI concordance (18/20) and a supply agreement with Siemens Healthineers. Radiopharm advanced RAD 202’s Phase 0/1 trial with DSMC clearance to 130 mCi dosing and initiated first-in-human studies for radiotherapeutics RV-01 and RAD 402.
| Metric | Value |
|---|---|
| Price | $4.58 |
| Market Cap | $37.45M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $50.82 |
| 52-Week Low | $3.50 |
| Volume | 12 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
2 analysts cover RADX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $22.50.